ARCHIVES OF FAMILY MEDICINE

MARCH 1994

CHAOTIC FAMILY DYNAMICS
B. W. H. Smith

THE UTILITY OF ELECTRONIC MAIL AS A MEDIUM FOR PATIENT-PHYSICIAN COMMUNICATION
R. A. Neill; A. G. Mainous III; J. R. Clark; M. D. Hagen

HEALTH SYSTEM REFORM: A PROVIDER OR A PATIENT PERSPECTIVE?
D. N. Mirvis

PRESENTATIONS OF DIABETIC FEET
M. A. Pliskin; W. F. Todd; G. W. Edelson

AN ORGANIZATIONAL STRATEGY TO IMPROVE ADOLESCENT MEASLES-MUMPS-RUBELLA VACCINATION IN A LOW SOCIOECONOMIC POPULATION: A METHOD TO REDUCE MISSED OPPORTUNITIES
P. G. Harper, D. M. Murray

AN ALGORITHM FOR SMOKING CESSION
J. R. Hughes

American Medical Association
Physicians dedicated to the health of America
INDEX TO ADVERTISERS

Astra-Merck Group of Merck & Co .... 228-230
Cerenex Pharmaceuticals, a Division of Glaxo ............... 224A-D
Knoll Pharmaceuticals ............... 272A-B
Lederle Laboratories ............... 208A-B
Marion Merrell Dow Inc .......... 256A-B
Miles Pharmaceuticals Inc .......... 240A-B
Roerig, A Division of Pfizer, Inc .... Cover 2-201
Rhone-Poulenc Rorer ............... 202-203, 216
G. D. Searle & Co ............... 207
SmithKline-Beecham Laboratories ........ 205
Syntex Laboratories ............. 239-240, Cover 3-Cover 4
3M Health Care ............... 213
Whitby Pharmaceuticals .......... 211
Wyeth-Ayerst Laboratories ......... 219-220

While every precaution is taken to ensure accuracy, we cannot guarantee against the possibility of an occasional change or omission in the preparation of this index.
6,515 days. 67,303,212 births in America. 37,326 major league baseball games. 5 presidents. 1 Halley's comet. 17 more NSAIDs. 17 nice tries. 0 reasons to change.

Contraindicated in patients hypersensitive to naproxen, aspirin, or other NSAIDs. As with other NSAIDs, the most frequent adverse events are gastrointestinal. With chronic NSAID therapy, serious GI toxicity such as bleeding, ulceration, and perforation can occur. Rare hepatic and renal reactions have been reported.

keep doing it with NAPROSYN (NAPROXEN) 500 mg tablets

Also available in 250 and 375 mg tablets and in suspension 125 mg/5 mL.

Please see brief summary of full prescribing information on adjacent page.

©1994 Syntex Puerto Rico, Inc. NP94035